Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Compass Therapeutics, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 201
- +31 vs. Q4 2025
- Shares held
- 173.7M
- +17.6M (+11.3%) vs. Q4 2025
- Total value
- $921.3M
- +$83.2M (+9.9%) vs. Q4 2025
- New holders
- 50
- 76 more added
- Sold out
- 19
- 47 more reduced
3 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 215 | $363.4M |
| Q1 2026 | 201 | $921.3M |
| Q4 2025 | 173 | $881.5M |
| Q3 2025 | 125 | $528.7M |
| Q2 2025 | 103 | $281.5M |
| Q1 2025 | 108 | $206.1M |
| Q4 2024 | 92 | $147.0M |
| Q3 2024 | 79 | $169.6M |
| Q2 2024 | 82 | $93.4M |
| Q1 2024 | 78 | $187.2M |
| Q4 2023 | 77 | $134.3M |
| Q3 2023 | 76 | $176.7M |
| Q2 2023 | 73 | $287.7M |
| Q1 2023 | 73 | $266.5M |
| Q4 2022 | 55 | $401.4M |
| Q3 2022 | 38 | $145.6M |
| Q2 2022 | 34 | $163.9M |
| Q1 2022 | 34 | $85.4M |
| Q4 2021 | 37 | $201.6M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Compass Therapeutics, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 16,790,809 | $88.8M | 4.51% | 00.0% | Unchanged |
| Trails Edge Capital Partners, LP | 0 | $0 | 0.00% | −1,415,273−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −1,263,647−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −245,532−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −210,249−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −205,024−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −133,810−100.0% | Sold out |
| NEOS Investment Management LLC | 0 | $0 | 0.00% | −101,676−100.0% | Sold out |
| CM Management, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −81,449−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −70,063−100.0% | Sold out |
| Caxton Corp | 0 | $0 | 0.00% | −29,495−100.0% | Sold out |
| Avanza Fonder AB | 0 | $0 | 0.00% | −27,347−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −15,200−100.0% | Sold out |
| Flagship Harbor Advisors, LLC | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −4,867−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −4,111−100.0% | Sold out |
| Cape Investment Advisory, Inc. | 0 | $0 | 0.00% | −2,002−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −526−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Financial Advisory Corp | – | – | – | – | Not filed |
| CIBC Private Wealth Group, LLC | – | – | – | – | Not filed |